Trial Profile

A Phase 1b open-label, randomized study of ANAVEX3-71 in healthy male and female adults

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 13 Nov 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs ANAVEX3-71 (Primary) ; ANAVEX3-71 (Primary)
Indications Alzheimer's disease; Frontotemporal dementia; Neurodegenerative disorders; Schizophrenia
Focus Adverse reactions
Acronyms ANAVEX3-71-002

Most Recent Events

13 Nov 2025 New trial record
02 Oct 2025 Results presented in a Anavex Life Sciences media release.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com